Claims for Patent: 9,682,144
✉ Email this page to a colleague
Summary for Patent: 9,682,144
Title: | Composition comprising inhibitors of IRS-1 and of VEGF |
Abstract: | The present invention relates to a composition or kit of parts comprising an inhibitor of IRS-1 and an inhibitor of the VEGF pathway and to the use thereof for treating an angiogenic disease. |
Inventor(s): | Thorin; Eric (Montreal, CA), Al-Mahmood; Salman (Paris, FR), Colin; Sylvie (Paris, FR), Ferry; Antoine (Paris, FR), Viaud; Eric (Lausanne, CH) |
Assignee: | GENE SIGNAL INTERNATIONAL, SA (CH) |
Application Number: | 14/130,246 |
Patent Claims: | 1. A method for treating an angiogenic disease comprising administering a synergistic therapeutically effective amount of an inhibitor of insulin receptor substrate-1
(IRS-1) expression and an inhibitor of vascular endothelial growth factor (VEGF) pathway, wherein the inhibitor of IRS-1 is an IRS-1 antisense oligonucleotide consisting of a sequence SEQ ID NO: 2, or any function conservative sequence of SEQ ID NO: 2
selected from the group consisting of SEQ ID NO: 3 to 21 and wherein the inhibitor of the VEGF pathway is the anti-VEGF antibody, ranibizumab, wherein: the synergistic therapeutically effective amount of the inhibitor of insulin receptor substrate-1
(IRS-1) is such that an amount of 0.5 .mu.g may be administered to a subject in need thereof; and the synergistic therapeutically effective amount of an inhibitor of the anti-VEGF antibody, ranibizumab is such that an amount of 25 ng may be administered
to a subject in need thereof.
2. The method of claim 1, wherein the angiogenic disease is an ocular angiogenic disease. |
Details for Patent 9,682,144
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | 06/30/2006 | ⤷ Try a Trial | 2031-06-30 |
Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | 08/10/2012 | ⤷ Try a Trial | 2031-06-30 |
Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | 10/13/2016 | ⤷ Try a Trial | 2031-06-30 |
Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | 03/20/2018 | ⤷ Try a Trial | 2031-06-30 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.